Clinical Trial

Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-04-23; most recent amendment 2025-08-26.
Status change: Not Yet Recruiting → Recruiting 2022-07-21
Trial Details
NCT Number NCT04863950
Lead Sponsor The University of Texas Health Science Center at San Antonio
Conditions Glioblastoma
Enrollment 25 participants
Start Date 2022-05-25
Primary Completion 2026-08 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-27